Zero Type 1 diabetes cases by 2047 a revolutionary dream from Nagpur: CM
Tired of too many ads? go ad free now
Calling it a "revolutionary dream from Nagpur", Fadnavis said, "The goal set by diabetes experts to prevent new cases of Type 1 diabetes by 2047 is a bold and visionary one. Remarkably, this idea took root right here in Nagpur."
Fadnavis was speaking while inaugurating the 12th edition of the Hello Diabetes Academia (HDA). The concept was explained by Dr Sunil Gupta, the organising chairman of the conference and a former national president of the Diabetes in Pregnancy Study Group of India (DIPSI).
"If a woman maintains normal sugar levels before and during pregnancy, the risk of type 1 diabetes in the child can be significantly reduced. DIPSI is conducting awareness programmes in multiple Indian languages to educate women about the importance of sugar control even before conception.
"
He further said, "Our vision is to ensure that by the year 2047, India sees no new cases of type 1 diabetes, thanks to proactive maternal health education."
Among the guests present at the event were Dr Rati Makkar, Padma Shri Dr Shashank Joshi, Padma Shri Dr Kamalakar Tripathi, Dr AK Das, Dr Banshi Saboo, Dr Vinky Rughwani and Dr Kavita Gupta, along with a host of national and international diabetes specialists and academicians.
Speaking about the larger health crisis posed by diabetes and obesity, Fadnavis said, "Rapid urbanisation and the resulting unhealthy food habits are causing lifestyle diseases to emerge at younger ages.
Tired of too many ads? go ad free now
Such conferences play a vital role in creating awareness and empowering people to adopt healthier lifestyles."
The CM highlighted the efforts of the 'Fit India Movement' launched by Prime Minister Narendra Modi. "Public awareness is the most powerful remedy against lifestyle diseases," he said.
Fadnavis also appreciated the consistent efforts of Dr Sunil Gupta, saying, "He organised countless programmes across India, published research, and built platforms for awareness."
The HDA 2025 conference features over 150 sessions, workshops and presentations on diabetes prevention, treatment strategies, endocrinology and lifestyle management.
# DIPSI's road map
- Promoting sugar control even before conception through pre-pregnancy counselling
- Screening all pregnant women early for gestational diabetes using a simple single-test method
- Educating mothers in all Indian languages about maintaining normal glucose levels during pregnancy
- Organising awareness camps and workshops across rural and urban India
- Preventing intergenerational transmission by targeting maternal blood sugar control
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
2 hours ago
- News18
Monsoon Health Alert: What's Covered, What's Not In Vector-Borne Illness Insurance
Last Updated: Good health insurance becomes the need of the hour that thwarts individuals against falling into any untoward financial trap while dealing with these diseases. Monsoon Health Alert: The rainy season in the Indian subcontinent which is also called 'Monsoon' not only brings relief from scorching heat to people, but also provides a suitable condition for the growth of mosquitoes and other insects. They are also the carriers of many vector-borne diseases, leading to a rise in diseases related to monsoon. But beyond the physical discomfort, these illnesses come with a financial sting. Treatment costs in metro cities can run up to Rs 1 lakh, factoring in hospitalisation, diagnostic tests, and post-recovery care. 'These illnesses are not only physically taxing but can also be financially draining," says Siddharth Singhal, Head, Health Insurance at Thus, good health insurance becomes the need of the hour that thwarts individuals against falling into any untoward financial trap while dealing with these diseases. The Hidden Cost Of Recovery The typical recovery period for Dengue or Malaria ranges from 7 to 10 days, during which multiple consultations, lab tests, and follow-up medications are often required. While many health insurance plans cover hospitalisation, what often slips under the radar is the cost of outpatient care (OPD)—an expense that can quickly add up. 'This is where a comprehensive health insurance policy plays a vital role," Singhal explains. 'Including OPD cover ensures you're not caught off guard by routine but essential costs like doctor visits and diagnostics." With the right plan, patients can access quality care without worrying about out-of-pocket expenses every time they consult a doctor. Designed either as a standalone option or an add-on to existing plans, the coverage isn't seasonal—it offers year-round protection, which is especially helpful since such diseases can occur even outside the monsoon months. 'This plan is ideal for those without existing health coverage or anyone looking to strengthen their current policy with focused, illness-specific protection," Gupta adds. How Much Do Claims Usually Cost? Claim sizes vary depending on the severity of the disease and the hospitalisation duration. 'The costs usually involve room charges, ICU stays, lab tests, and medication—these are often overlooked during financial planning," says a Policybazaar spokesperson. In major cities, a hospital stay for Dengue or Malaria can cost anywhere between Rs 50,000 to Rs 1 lakh. Even a non-hospitalised case requiring frequent OPD visits and tests can end up being a costly affair. First Published: July 04, 2025, 06:30 IST
The Hindu
3 hours ago
- The Hindu
A new BHARAT- establishing baseline health parameters for the Indian population
We don't all age the same way, but we all do age. We intuitively recognise frailty when things start to slow down. Ageing unfolds at different rates, over time, between individuals, within and across populations. Often, it happens in bursts. Ageing is complicated. It is driven by molecular and cellular interactions and is shaped by one's environment, lifestyle, and socioeconomic conditions. This means one's chronological age often doesn't reflect how old one's body really is. Since researchers discovered in 1935 that ageing can be altered, they have been looking for reliable biological clues, called biomarkers, that in isolation or together can indicate how old our bodies are and how they might respond to factors such as diet, exercise, etc. Biomarkers of ageing Last year, the Indian Institute of Science (IISc), Bengaluru, launched a large-scale study called BHARAT, short for 'Biomarkers of Healthy Aging, Resilience, Adversity, and Transitions', as part of its Longevity India Program. The study aims to map the physiological, molecular, and environmental indicators that drive ageing in the Indian population. 'We lack clear information on what features define or influence healthy ageing,' says Deepak Kumar Saini, convener of BHARAT and professor of development biology and genetics at IISc. 'We are building an information portal to understand the rules of healthy ageing in Indians.' Worldwide, life expectancy has risen significantly over the past few decades. In India it climbed 4.1 years to 67.3 in the first two decades of this century. Living longer doesn't mean living healthier, however. Studies have predicted a 168% increase in Parkinson's disease cases in India by 2050 and a 200% rise in dementia across low- and middle-income countries. Yet much of what we know about health and disease risk comes from studies in Western populations, which means the diagnostic tools, biomarkers, and even treatments may not be optimal for people in India or other non-Western countries. Gaps for patients in Global South This limited focus has created a gap between population-based biomarkers and diagnostic cut-offs for people in the Global South. This can lead to misdiagnosis and treatments that don't reflect how diseases progress or respond to therapeutics in different groups. 'Western values for cholesterol, vitamin D, or B12 may label many Indians as deficient. But are these truly abnormal within our context? Our study aims to answer that. We are not only identifying biomarkers for healthy ageing but also building the Bharat Baseline — a reliable reference for what is normal in the Indian population,' Prof. Saini says. Earlier this year, researchers from Sichuan, China, reported in Scientific Reports that certain biomarkers for breast cancer, such as high levels of high-density lipoprotein cholesterol, could signal an elevated risk in European populations but may serve as supportive indicators in Asians. 'We see differences in inflammatory markers. For instance, C-reactive protein (CRP) levels tend to be elevated in Indians even without acute illness. This inflammation often results from early-life infections, environmental toxins, or chronic nutritional and metabolic issues,' Shawn T. Joseph, senior consultant, head and neck surgical oncology, VPS Lakeshore Hospital in Kochi, says. 'Applying Western CRP cut-offs risks missing early warning signs of cardiovascular or metabolic disease in Indian patients,' he adds. An India-specific database BHARAT's goal is to change this. Its database will include genomic biomarkers (like mutations linked to disease susceptibility), proteomic and metabolic indicators (reflecting biological pathways and metabolic health), and environmental and lifestyle factors. Identifying early warning signs of age-related changes can enable better prediction, intervention, and potentially delay the onset of disease. There is a need for proactive markers of health, indicators that can tell when an organ is functioning below its optimal level, even if it is not yet diseased. For instance, your liver age is more than your chronological age. To do that, researchers must sift through large, many-dimensional datasets and plan to take the help of artificial intelligence (AI) models. 'AI and machine learning are essential to integrate and analyse layered data to see the full picture. It can simulate the impact of interventions and augment existing datasets to improve signal detection that may otherwise be missed in high-dimensional, small-sample studies. This will help us choose the most effective interventions before launching costly trials,' says Tavpritesh Sethi, professor of computational biology at the Indraprastha Institute of Information Technology, Delhi, who is also one of the investigators of BHARAT. However, if the AI models' training datasets don't reflect local realities, they risk perpetuating health inequities. India's population is genetically, environmentally, and socioeconomically diverse. Capturing this diversity in a single database is crucial but also logistically complex. Prof Saini anticipates a few challenges, including the difficulty of obtaining samples from healthy adults, securing long-term government and philanthropic funding, and expanding the study to collect samples from across the country. (Rupsy Khurana is science communication and outreach lead at the National Centre for Biological Sciences, Bengaluru.
Time of India
3 hours ago
- Time of India
Consumer health cos woo Gen Z with chewables
NEW DELHI: Gen Z's preference for trendy, convenient, and non-pill OTC formats such as gummies, chewables and effervescent powders, combined with rising health awareness, is fuelling significant growth in India's consumer healthcare market. The trend is driving strong investments in innovation as companies including Haleon India, Dabur and Rasna seek to capitalise on emerging consumer trends and diverse cohorts. Despite sluggish demand, companies continue to invest steadily in innovation - both organically and through acquisitions - being aware that returns typically require a longer-term horizon. For some, like Haleon India (formerly GlaxoSmithKline Consumer Healthcare), this strategy is already paying off. The company achieved a high single-digit revenue growth in the quarter ended March 2025, outperforming other Asia-Pacific markets, including China. The UK-based giant, with revenues exceeding over $14.3 billion, plans to democratise healthcare in India - where high costs remain a barrier - by focusing on small, affordable packs of its leading brands tailored for value-conscious consumers, according to Navneet Saluja, general manager, Indian sub-continent, Haleon. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 2025 Top Trending local enterprise accounting software [Click Here] Esseps Learn More Undo Innovative formats like gummies, effervescent tablets, chewables, and liquid drops are gaining traction, driven by direct-to-consumer brands in India's over Rs 40,000 crore consumer healthcare market. This mirrors global trends, where convenience, palatability, and visual appeal are key factors shaping consumer preferences. Homegrown FMCG company Dabur has undertaken a comprehensive refresh of its 'Vision' strategy to achieve a sustainable double-digit CAGR by FY28 in both topline and bottomline. Says Dabur India CEO Mohit Malhotra: "Premiumisation and contemporisation across categories is a key pillar of this strategy. Some categories that we will be looking at include, gummies, powders and effervescent in the healthcare business. In addition, we have been increasing the relevance of our time-tested and efficacious products by introducing new age formats". And, to cater to health-conscious Gen Z, Rasna, a mass-market beverage brand, recently acquired ready-to-drink (RTD) brand Jumpin from Hershey's India. Piruz Khambatta, group chairman of Rasna says the company plans to tap into India's booming non-carbonated RTD market, with a vitamin-fortified fruit juice beverage that has low sugar content. These moves reflect a broader trend: The demand for convenient, on-the-go product options is rapidly expanding, unlocking strong growth potential in India. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
